Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both semaglutide (Ozempic) and tirzepatide (Mounjaro) are GLP-1 receptor agonists that reduce hunger and improve blood sugar control, but they work through different biological pathways. Clinical evidence shows tirzepatide produces more substantial weight loss than semaglutide alone, with some patients losing up to 22% of body weight over 68 weeks.

How Semaglutide and Tirzepatide Differ Mechanically

Semaglutide activates only the GLP-1 receptor, a single hormone pathway that slows stomach emptying and signals satiety to the brain. Tirzepatide is a dual agonist, meaning it activates both GLP-1 and GIP receptors simultaneously, engaging two separate appetite-suppression mechanisms at once.

The SURMOUNT clinical trial program demonstrated that tirzepatide users experienced weight losses ranging from 16% to 22% of body weight depending on dose level, compared to 9% to 13% for semaglutide users over comparable timeframes. This difference reflects the additive effect of targeting two hormone pathways instead of one.

GIP activation appears to enhance insulin sensitivity and boost energy expenditure beyond what GLP-1 activity alone produces. Patients on tirzepatide frequently report feeling fuller faster and maintaining satisfaction longer between meals, contributing to sustained caloric deficit without restriction.

Weight Loss Results: Clinical Trial Comparisons

The SURMOUNT-4 trial directly compared semaglutide and tirzepatide in patients with obesity and type 2 diabetes. At the 68-week mark, tirzepatide at 15 mg produced a mean weight loss of 21%, while semaglutide at 2.4 mg (the highest approved dose) achieved approximately 14% weight loss.

Responder rates also favored tirzepatide: approximately 85% of participants achieved at least 5% weight loss, and over 50% reached 15% or greater weight loss reductions. For semaglutide, approximately 67% achieved 5% weight loss and 34% exceeded 15%, indicating broader and deeper responses with dual-hormone therapy.

Individual outcomes vary significantly based on genetic predisposition to peptide signaling. PlexusDx's Precision Peptide Genetic Test evaluates key variants (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) that predict which patients will experience superior results with GIP-pathway activation versus GLP-1-only therapy.

Side Effect Profiles and Patient Tolerance

Gastrointestinal side effects occur more frequently with tirzepatide than semaglutide, with nausea, vomiting, and constipation reported in up to 25% of users during dose escalation. Semaglutide carries a lower incidence of severe GI symptoms, making it preferable for patients with baseline digestive sensitivity.

Tirzepatide's greater potency means faster appetite suppression can trigger nausea in the first 2–4 weeks of treatment; this typically resolves as the body adapts. Slower dose titration and consistent meal timing often minimize gastrointestinal adjustments. Most patients report that side effects diminish significantly after the first month.

Pancreatitis, thyroid concerns, and gallbladder issues have been documented with both medications at comparable rates. Patients with personal or family history of medullary thyroid carcinoma should avoid both agents. PlexusDx clinical coordinators review full medical history before recommending either treatment pathway.

Cost, Accessibility, and PlexusDx Compounded Options

PlexusDx offers compounded tirzepatide injection starting at $249 per month from licensed 503A compounding pharmacies, with no insurance requirement and HSA/FSA eligibility. Branded Mounjaro typically costs $1,000–$1,400 monthly with commercial insurance, making compounded tirzepatide significantly more affordable for self-pay patients.

PlexusDx also provides compounded semaglutide injection beginning at $149 per month, alongside oral tirzepatide ($279/mo) and oral semaglutide ($249/mo) for patients preferring needle-free administration. The dual-compound GLP-Squared Injection combines both semaglutide and tirzepatide at $249/mo, offering personalized pathway optimization.

Precision Peptide Genetic Testing ($99 add-on after first treatment month) identifies individual peptide-receptor sensitivities across 14 biological pathways and 150+ genetic insights, enabling treatment adjustment toward the compound and dose strategy most likely to yield superior weight loss in your unique genetic profile. Your dose may need to go up. Your price won't.

Who Benefits Most From Tirzepatide vs. Semaglutide

Patients seeking maximum weight loss in the shortest timeframe and with no prior GLP-1 exposure often achieve best outcomes with tirzepatide, provided gastrointestinal side effects can be managed through gradual titration. Those with baseline nausea, severe IBS, or pancreatitis history may benefit from semaglutide's gentler single-pathway approach.

Individuals with type 2 diabetes alongside obesity frequently experience superior glycemic control with tirzepatide because GIP agonism directly enhances insulin secretion and reduces hepatic glucose production. Semaglutide alone controls blood sugar effectively but lacks the additional metabolic advantage of GIP activation.

Prior treatment failure or plateau on semaglutide is an ideal indicator for tirzepatide transition, as dual-receptor activation circumvents weight-loss resistance caused by single-pathway adaptation. Conversely, semaglutide responders seeking cost optimization or reduced GI burden may remain stable and satisfied on lower-cost compounded semaglutide long-term.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I switch from Ozempic (semaglutide) to Mounjaro (tirzepatide) if I'm not losing enough weight?

Yes, many patients transition successfully from semaglutide to tirzepatide when weight loss plateaus. Because tirzepatide engages an additional GIP-receptor pathway, dual agonism frequently overcomes single-pathway adaptation. PlexusDx can facilitate this transition with compounded tirzepatide injection starting at $249/mo, and the Precision Peptide Genetic Test helps confirm whether your genetic profile predicts superior response to GIP activation.

Is tirzepatide significantly more effective than semaglutide in clinical studies?

Yes. The SURMOUNT-4 trial showed tirzepatide at 15 mg produced 21% weight loss versus 14% for semaglutide at 2.4 mg over 68 weeks. Tirzepatide also achieved higher responder rates (85% achieved ≥5% loss vs. 67% for semaglutide), and more patients reached ≥15% weight loss benchmarks. These differences reflect tirzepatide's dual GLP-1/GIP mechanism versus semaglutide's single GLP-1 pathway.

How much does compounded tirzepatide cost through PlexusDx?

PlexusDx's compounded tirzepatide injection starts at $249 per month from licensed 503A compounding pharmacies, with no insurance needed and HSA/FSA eligibility. Branded Mounjaro typically costs $1,000+ monthly even with insurance, making compounded tirzepatide substantially more accessible. Your dose may need to go up. Your price won't.

Does tirzepatide cause more side effects than semaglutide?

Tirzepatide carries a higher incidence of nausea, vomiting, and constipation during dose escalation—up to 25% of users report GI symptoms, compared to lower rates with semaglutide. However, these side effects typically resolve within 2–4 weeks as the body adapts. Slower titration and consistent meal timing minimize discomfort. Semaglutide may be preferable for patients with baseline digestive sensitivity or pancreatitis history.

How can genetic testing help me choose between semaglutide and tirzepatide?

PlexusDx's Precision Peptide Genetic Test ($99 add-on) evaluates key variants including GIPR rs1800437 and GLP1R rs6923761 that predict superior response to GIP-pathway activation versus GLP-1-only therapy. By mapping 14 peptide pathways and 150+ genetic insights, the test identifies which compound and dose strategy aligns with your unique biology, maximizing weight loss and minimizing side effects before committing to longer-term treatment.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves